CA3041253A1 - Validation of continuous viral clearance - Google Patents
Validation of continuous viral clearance Download PDFInfo
- Publication number
- CA3041253A1 CA3041253A1 CA3041253A CA3041253A CA3041253A1 CA 3041253 A1 CA3041253 A1 CA 3041253A1 CA 3041253 A CA3041253 A CA 3041253A CA 3041253 A CA3041253 A CA 3041253A CA 3041253 A1 CA3041253 A1 CA 3041253A1
- Authority
- CA
- Canada
- Prior art keywords
- sampling
- viral
- probe
- cfi
- continuous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003612 virological effect Effects 0.000 title claims abstract description 86
- 238000010200 validation analysis Methods 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 77
- 239000000523 sample Substances 0.000 claims abstract description 77
- 238000005070 sampling Methods 0.000 claims abstract description 56
- 238000012421 spiking Methods 0.000 claims abstract description 20
- 230000002779 inactivation Effects 0.000 claims description 39
- 238000000265 homogenisation Methods 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 238000010924 continuous production Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 238000011002 quantification Methods 0.000 claims description 6
- 241000700605 Viruses Species 0.000 description 35
- 238000004587 chromatography analysis Methods 0.000 description 32
- 230000008569 process Effects 0.000 description 13
- 238000010977 unit operation Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010950 spiking study Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000022120 Jeavons syndrome Diseases 0.000 description 2
- 241000252067 Megalops atlanticus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003889 chemical engineering Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012791 spiking procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013469 resistive pulse sensing Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/22—Testing for sterility conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16194959.9 | 2016-10-21 | ||
| EP16194959.9A EP3141611A3 (en) | 2016-10-21 | 2016-10-21 | Validation of continuous viral clearance |
| PCT/US2017/057298 WO2018075716A1 (en) | 2016-10-21 | 2017-10-19 | Validation of continuous viral clearance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3041253A1 true CA3041253A1 (en) | 2018-04-26 |
Family
ID=57209212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041253A Abandoned CA3041253A1 (en) | 2016-10-21 | 2017-10-19 | Validation of continuous viral clearance |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10894991B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3141611A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019537435A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190066017A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110100008A (cg-RX-API-DMAC7.html) |
| AR (1) | AR109846A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017345412A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019007835A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3041253A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL266095A (cg-RX-API-DMAC7.html) |
| MX (1) | MX385466B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2755634C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG10202104023QA (cg-RX-API-DMAC7.html) |
| TW (1) | TW201827830A (cg-RX-API-DMAC7.html) |
| UY (1) | UY37447A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018075716A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019011900A1 (en) * | 2017-07-10 | 2019-01-17 | Baxalta Incorporated | METHOD FOR LIQUID INCUBATION AND VIRUS INACTIVATION |
| EP4112735A4 (en) * | 2020-02-28 | 2023-09-06 | Asahi Kasei Medical Co., Ltd. | Method for evaluating viral clearance performance |
| CN116261566A (zh) * | 2020-09-21 | 2023-06-13 | 拜耳医药保健有限责任公司 | 病原体清除系统和方法 |
| US12203914B2 (en) * | 2020-11-12 | 2025-01-21 | Sartorius Bioanalytical Instruments, Inc. | Viral clearance evaluation for biological medical product preparation processes |
| EP4317460B1 (en) * | 2021-03-26 | 2025-12-31 | Asahi Kasei Life Science Corporation | VIRAL CLEARANCE TEST PROCEDURE |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG184833A1 (en) * | 2010-04-14 | 2012-11-29 | Emd Millipore Corp | Methods of producing high titer, high purity virus stocks and methods of use thereof |
| AU2014100888A4 (en) * | 2014-08-07 | 2014-09-11 | Novartis Ag | Virus clearance and protein purification methods |
-
2016
- 2016-10-21 EP EP16194959.9A patent/EP3141611A3/en not_active Withdrawn
-
2017
- 2017-10-19 JP JP2019520956A patent/JP2019537435A/ja not_active Ceased
- 2017-10-19 MX MX2019004540A patent/MX385466B/es unknown
- 2017-10-19 BR BR112019007835A patent/BR112019007835A2/pt not_active IP Right Cessation
- 2017-10-19 TW TW106135849A patent/TW201827830A/zh unknown
- 2017-10-19 CN CN201780064932.4A patent/CN110100008A/zh active Pending
- 2017-10-19 KR KR1020197010823A patent/KR20190066017A/ko not_active Ceased
- 2017-10-19 WO PCT/US2017/057298 patent/WO2018075716A1/en not_active Ceased
- 2017-10-19 AU AU2017345412A patent/AU2017345412A1/en not_active Abandoned
- 2017-10-19 RU RU2019115375A patent/RU2755634C2/ru active
- 2017-10-19 SG SG10202104023QA patent/SG10202104023QA/en unknown
- 2017-10-19 CA CA3041253A patent/CA3041253A1/en not_active Abandoned
- 2017-10-19 EP EP17791896.8A patent/EP3529367A1/en not_active Withdrawn
- 2017-10-20 UY UY0001037447A patent/UY37447A/es not_active Application Discontinuation
- 2017-10-20 US US16/343,125 patent/US10894991B2/en not_active Expired - Fee Related
- 2017-10-20 AR ARP170102921A patent/AR109846A1/es not_active Application Discontinuation
-
2019
- 2019-04-17 IL IL266095A patent/IL266095A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110100008A (zh) | 2019-08-06 |
| EP3529367A1 (en) | 2019-08-28 |
| AU2017345412A1 (en) | 2019-04-18 |
| MX2019004540A (es) | 2019-06-12 |
| IL266095A (en) | 2019-06-30 |
| RU2755634C2 (ru) | 2021-09-17 |
| US20190316213A1 (en) | 2019-10-17 |
| KR20190066017A (ko) | 2019-06-12 |
| JP2019537435A (ja) | 2019-12-26 |
| WO2018075716A1 (en) | 2018-04-26 |
| RU2019115375A3 (cg-RX-API-DMAC7.html) | 2021-03-19 |
| SG10202104023QA (en) | 2021-06-29 |
| MX385466B (es) | 2025-03-18 |
| EP3141611A2 (en) | 2017-03-15 |
| US10894991B2 (en) | 2021-01-19 |
| BR112019007835A2 (pt) | 2019-10-01 |
| UY37447A (es) | 2018-05-31 |
| EP3141611A3 (en) | 2017-05-10 |
| RU2019115375A (ru) | 2020-11-23 |
| AR109846A1 (es) | 2019-01-30 |
| TW201827830A (zh) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10894991B2 (en) | Validation of continuous viral clearance | |
| US10415076B2 (en) | High throughput quantification and characterization of foot and mouth disease virus and products thereof | |
| US11965018B2 (en) | Chromatography system and method for capturing a biopolymer | |
| EP3981873A1 (en) | Methods for inactivating viruses during a protein purification process | |
| CN104049025A (zh) | 微量注射泵驱动液流的毛细管电泳分析系统 | |
| EA034347B1 (ru) | Способ инактивации вирусов при получении антител | |
| Guo et al. | Sensitive determination of four tetracycline antibiotics in pig plasma by field-amplified sample stacking open-tubular capillary electrochromatography with dimethylethanolamine aminated polychloromethyl styrene nano-latex coated capillary column | |
| Kirchner et al. | Determination of vitamin B12 in infant formula and adult nutritionals using HPLC after purification on an immunoaffinity column: First action 2011.09 | |
| TWI698529B (zh) | 連續流動系統中保持窄滯留時間分布的方法 | |
| JP2010537197A (ja) | 液体クロマトグラフィー溶離液を排流するためのシステム及び方法 | |
| US20190359930A1 (en) | Method for sampling fluid streams for monitoring contaminants in a continuous flow | |
| HK40011645A (en) | Validation of continuous viral clearance | |
| JP5948630B2 (ja) | 質量分析を用いた定量分析方法と定量分析装置 | |
| CN114729916B (zh) | 产品品质属性测量 | |
| CN105301127A (zh) | 一种利巴韦林药物组合物及其有关物质检测方法 | |
| TW201900865A (zh) | 連續流動系統中保持窄滯留時間分布的機械方法 | |
| CN107024554A (zh) | 一种血清中全氟化合物的检测装置 | |
| CN104302362A (zh) | 用于物质纯化的设备 | |
| US20230110811A1 (en) | pH METER CALIBRATION AND CORRECTION | |
| AU2016221726B2 (en) | Method for quantification of virus particles using capillary zone electrophoresis | |
| Kikuchi et al. | Virus clearance by activated carbon for therapeutic monoclonal antibody purification | |
| CN107991412A (zh) | 高效液相色谱法测定阿哌沙班杂质含量的方法 | |
| Nissankararao et al. | Dissolution method development and validation: a review | |
| CN109387581B (zh) | 一种口蹄疫抗原的定量方法 | |
| CN105954421B (zh) | 一种冻干粉针中的杂质的气相色谱检测方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20240130 |